Trial Profile
TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar) for recurrent nasopharyngeal carcinoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 11 May 2018 New trial record